治疗药物监测 (Therapeutic Drug Monitoring)
October 2024 - Volume 46 - Issue 4
https://journals.lww.com/drug-monitoring/toc/2024/08000

大查房（Grand Round）
1.丙戊酸与多鲁特韦之间的药物相互作用管理——病例研究（Management of the Drug–Drug Interactions Between Valproic Acid and Dolutegravir—A Case Study）
Cattaneo, Dario; Giacomelli, Andrea; Calvagna, Nunziata; More
Therapeutic Drug Monitoring. 46(4):419-421, August 2024.

综述文章（Review Article）
2.基于随机对照试验的程序性死亡1/程序性死亡配体1联合细胞毒性T淋巴细胞相关抗原4抑制剂治疗晚期或转移性非小细胞肺癌的疗效和安全性：一项荟萃分析（Efficacy and Safety of Programmed Death 1/Programmed Death-Ligand 1 Plus
Cytotoxic T-Lymphocyte–Associated Antigen 4 Inhibitors for Advanced or Metastatic Non–Small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials）
Ren, Wei; Fang, Yingying; He, Yujing; More
Therapeutic Drug Monitoring. 46(4):422-433, August 2024.

原创文章（Original Article）
3. 评估已发表的群体药动学模型以指导成年肺移植受者的他克莫司治疗（Evaluation of Published Population Pharmacokinetic Models to Inform Tacrolimus Therapy in Adult Lung Transplant Recipients）
Kirubakaran, Ranita; Singh, Rani M.; Carland, Jane E.; More
Therapeutic Drug Monitoring. 46(4):434-445, August 2024.
4.他克莫司在肝移植受者中的监测，移植后胆汁淤积：两种商业免疫测定法与液相色谱-串联质谱法的比较（Tacrolimus Monitoring in Liver Transplant Recipients, Posttransplant Cholestasis: A Comparative Between 2 Commercial Immunoassays and a
Liquid Chromatography-Tandem Mass Spectrometry Method）
Parant, François; Delignette, Marie-Charlotte; Charpiat, Bruno; More
Therapeutic Drug Monitoring. 46(4):446-455, August 2024.
5. 他克莫司患者内变异性对肝移植后同种异体排斥反应频率和存活率的影响(Influence of Tacrolimus Intrapatient Variability on Allograft Rejection Frequency and Survival Following Liver Transplantation)
Soares, Maria Eduarda; Costa, Gabriela; Guerra, Laura; More
Therapeutic Drug Monitoring. 46(4):456-459, August 2024.
6.基于荧光的侧流免疫测定法用于英夫利昔单抗的定量：分析和临床性能评估( Fluorescence-Based Lateral Flow Immunoassay for Quantification of Infliximab: Analytical and Clinical Performance Evaluation)
Kim, Eun Sil; Chon, Hyangah; Kwon, Yiyoung; More
Therapeutic Drug Monitoring. 46(4):460-467, August 2024.
7. 使用LC-HRMS/MS定量人血浆中的依法韦伦羟基代谢物(Quantification of Efavirenz Hydroxymetabolites in Human Plasma Using LC-HRMS/MS)
Pettersson Bergstrand, Madeleine; Soeria-Atmadja, Sandra; Barclay, Victoria; More
Therapeutic Drug Monitoring. 46(4):468-476, August 2024.
8.开发、验证和临床应用超高效液相色谱串联质谱法测定人血清中10种抗结核药物(Development, Validation, and Clinical Application of an Ultra–High-Performance Liquid Chromatography Coupled With Tandem Mass Spectrometry Method for the
Determination of 10 Antituberculosis Drugs in Human Serum)
Fan, Xudong; Guo, Suhang; Zhang, Ruoying; More
Therapeutic Drug Monitoring. 46(4):477-484, August 2024.
9. 治疗监测帕博西尼、瑞博西尼、阿贝莫司他、M2、M20和来曲唑在人血浆中的浓度：一种新型LC-MS/MS方法(Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS
Method)
Posocco, Bianca; Zanchetta, Martina; Orleni, Marco; More
Therapeutic Drug Monitoring. 46(4):485-493, August 2024.
10. 分析验证体积吸收微采样方法用于治疗药物监测口服靶向抗癌药物，阿比特龙、阿来替尼、卡博替尼、伊马替尼、奥拉帕尼和舒尼替尼及其代谢物(Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug
Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and Metabolites)
Meertens, Marinda; de Vries, Niels; Rosing, Hilde; More
Therapeutic Drug Monitoring. 46(4):494-502, August 2024.
11.影响儿童癫痫患者血浆中丙戊酸浓度的因素及CYP2C9基因型在个体化丙戊酸治疗中的临床意义(Factors Influencing Plasma Concentrations of Valproic Acid in Pediatric Patients With Epilepsy and the Clinical Significance of CYP2C9 Genotypes in
Personalized Valproic Acid Therapy)
Ma, Bingsuo; Yang, Kun; Li, Xinping; More
Therapeutic Drug Monitoring. 46(4):503-511, August 2024.
12.基于生理药动学模型指导的母体舌下给药后新生儿唾液中丁丙诺啡的治疗监测( Salivary Therapeutic Monitoring of Buprenorphine in Neonates After Maternal Sublingual Dosing Guided by Physiologically Based Pharmacokinetic Modeling)
Alsmadi, Mo'tasem M.
Therapeutic Drug Monitoring. 46(4):512-521, August 2024.
13. 探针电喷雾电离串联质谱法检测和定量苯二氮卓类药物(Probe Electrospray Ionization Tandem Mass Spectrometry for the Detection and Quantification of Benzodiazepines)
Griffeuille, Pauline; El Balkhi, Souleiman; Dulaurent, Sylvain; More
Therapeutic Drug Monitoring. 46(4):522-529, August 2024.
14. 阿根廷孕妇精神活性物质使用情况的流行病学：一项测试母体头发的初步研究(Prevalence of Psychoactive Substance Use During Pregnancy in Argentine Women: A Pilot Study Testing Maternal Hair)
Vieiros, Melina; Mirahi, Afrouz; Villarreal, Marina; More
Therapeutic Drug Monitoring. 46(4):530-536, August 2024.
 短通讯(Short Communication)
15. 采用有限采样策略预测达托霉素暴露量(Daptomycin Exposure Prediction With a Limited Sampling Strategy)
De Gregori, Simona; Seminari, Elena; Capone, Mara; More
Therapeutic Drug Monitoring. 46(4):537-542, August 2024.
16.万古霉素蛋白结合与年龄相关变化：是时候认真对待了吗？(Age-Related Changes in Vancomycin Protein Binding: Is It Time to Take It Seriously?)
Gadsby, Jessica; Stachow, Lucy; Mulla, Hussain
Therapeutic Drug Monitoring. 46(4):543-547, August 2024.
17.妊娠前、中、后帕瑞肽药动学和细胞色素P450 3A4活性的变化(Changes in Perampanel Pharmacokinetics and Cytochrome P450 3A4 Activity Before, During, and After Pregnancy)
Yamamoto, Yoshiaki; Akita, Naoto; Nogimoto, Hiroki; More
Therapeutic Drug Monitoring. 46(4):548-551, August 2024.
致编辑的信(Letters to the Editor)
18.监测组织和血浆亚胺培南浓度用于治疗耐碳青霉烯类肠杆菌科细菌感染的坏死性筋膜炎——致编辑的信(Monitoring of Tissue and Plasma Imipenem Concentrations for the Treatment of Necrotizing Fasciitis With Carbapenem-Resistant
Enterobacteriaceae—A Letter to the Editor)
Dufraigne, Antonin; Perinel-Ragey, Sophie; Guitton, Jérôme; More
Therapeutic Drug Monitoring. 46(4):553-555, August 2024.
19.使用替代样本基质进行药物依从性监测：架起分析验证与临床解释之间的桥梁(Medication Adherence Monitoring Using Alternative Sample Matrices: Bridging the Gap Between Analytical Validation and Clinical Interpretation)
Zijp, Tanja R.; Izzah, Zamrotul; Touw, Daan J.; More
Therapeutic Drug Monitoring. 46(4):554-555, August 2024.
病例报告(Case Report)
20.抓住元凶：通过治疗药物监测在连续静脉血液滤过治疗的危重患者中确认的苯唑西林神经毒性(Catching the Culprit: Benzylpenicillin Neurotoxicity Confirmed by Therapeutic Drug Monitoring in a Critically Ill Patient With Continuous Venovenous
Hemofiltration)
van Gelder, Thomas G.; Schweitzer, Valentijn A.; Uijtendaal, Esther V.; More
Therapeutic Drug Monitoring. 46(4):556-558, August 2024.

治疗药物监测 (Therapeutic Drug Monitoring)
October 2024 - Volume 46 - Issue 5
https://journals.lww.com/drug-monitoring/toc/2024/10000

大查房（Grand Round）
1.危重病人接受肾脏替代治疗时的个性化阿莫西林治疗：大查房（ Personalized Amoxicillin Therapy in a Critically Ill Patient Undergoing Renal Replacement Therapy: A Grand Round）
Garrigue, Philippine; Reber, Margot; Perinel-Ragey, Sophie; More
Therapeutic Drug Monitoring. 46(5):559-562, October 2024.

 病例报告（Case Report）
2. 韩国再生障碍性贫血患者环孢素清除率不可预测及不良反应：病例研究（Unpredictable Cyclosporine Clearance in a Korean Patient With Aplastic Anemia With Adverse Effects: A Case Study）
Shihmanter, Renata; Miller, Edward B.; Shvartsman, Ekaterina; More
Therapeutic Drug Monitoring. 46(5):563-566, October 2024.

原创文章（Original Article）
3.印度狼疮性肾炎患者麦考酚酸莫非特的群体药动学和有限采样策略（Population Pharmacokinetics and Limited Sampling Strategy of Mycophenolate Mofetil for Indian Patients With Lupus Nephritis）
Koloskoff, Kévin; Panwar, Ritika; Rathi, Manish; More
Therapeutic Drug Monitoring. 46(5):567-574, October 2024.
4.开发参数和非参数模型以实现模型指导的精准剂量：针对肥胖患者的万古霉素质量改进努力（ Developing Parametric and Nonparametric Models for Model-Informed Precision Dosing: A Quality Improvement Effort in Vancomycin for Patients With
Obesity）
Hughes, Maria-Stephanie A.; Hughes, Jasmine H.; Endicott, Jeffrey; More
Therapeutic Drug Monitoring. 46(5):575-583, October 2024.
5. 接受连续肾脏替代治疗的患者未结合美罗培南的群体药动学模型：一项观察性队列研究（Population Pharmacokinetic Modeling of Unbound Meropenem in Patients Undergoing Continuous Renal Replacement Therapy: An Observational Cohort
Study）
Oda, Kazutaka; Jono, Hirofumi; Kamohara, Hidenobu; More
Therapeutic Drug Monitoring. 46(5):584-593, October 2024.
6.新的预测方程用于估计接受多粘菌素甲磺酸钠治疗的多药耐药革兰阴性细菌感染患者的血浆浓度（New Predictive Equation for the Estimation of Plasma Concentrations of Formed Colistin in Patients Treated With Colistimethate Sodium for
Multidrug-Resistant Gram-Negative Bacterial Infections）
Luque, Sonia; Sorlí, Luisa; Li, Jian; More
Therapeutic Drug Monitoring. 46(5):594-602, October 2024.
7.影响血液恶性肿瘤患者接受延迟释放片剂治疗的血清泊沙康唑浓度的因素（ Factors Influencing Serum Posaconazole Concentrations in Patients With Hematologic Malignancies Receiving Delayed-Release Tablets）
Yamada, Takaaki; Belabbas, Tassadit; Suetsugu, Kimitaka; More
Therapeutic Drug Monitoring. 46(5):603-610, October 2024.
8.日本接受真菌预防治疗的患者泊沙康唑的群体药动学模型（Population Pharmacokinetic Modeling of Posaconazole in Japanese Patients Receiving Fungal Prophylaxis）
Sugimoto, Mitsuhiro; Yonezawa, Atsushi; Kanda, Junya; More
Therapeutic Drug Monitoring. 46(5):611-618, October 2024.
9.评估临床实验室中英夫利昔单抗和阿达木单抗抗药物抗体检测的均质迁移率变化分析（ Evaluation of the Homogenous Mobility Shift Assay for Infliximab and Adalimumab Anti-drug Antibody Detection in the Clinical Laboratory）
Keating, Paula Elizabeth; Hock, Barry D.; Chin, Paul K. L.; More
Therapeutic Drug Monitoring. 46(5):619-626, October 2024.
10.开发和验证高效液相色谱紫外检测法以促进使用干血斑监测替考拉宁治疗（Development and Validation of a High-Performance Liquid Chromatography With Ultraviolet Detection Method to Facilitate Therapeutic Monitoring of Teicoplanin Using
Dried Blood Spots）
Ramadan, Ola; Opitz, Patrick; Hempel, Georg
Therapeutic Drug Monitoring. 46(5):627-633, October 2024.
11.通过液相色谱-质谱/质谱联用同时测定人血浆中的伊布替尼、二羟基伊布替尼和赞布替尼（ Simultaneous Determination of Ibrutinib, Dihydroxydiol Ibrutinib, and Zanubrutinib in Human Plasma by Liquid Chromatography–Mass Spectrometry/Mass
Spectrometry）
Guo, Yu-Jiao; Du, Tian-Tian; Yang, Yan-Ling; More
Therapeutic Drug Monitoring. 46(5):634-641, October 2024.
12.癫痫患者拉莫三嗪血浆浓度与疗效和毒性的关联：一项回顾性研究（Association of Lamotrigine Plasma Concentrations With Efficacy and Toxicity in Patients With Epilepsy: A Retrospective Study）
Lee, Ze-Ning; van Nuland, Merel; Bognàr, Tim; More
Therapeutic Drug Monitoring. 46(5):642-648, October 2024.
13. 中国癫痫患者拉莫三嗪及其N2-葡糖苷酸代谢物的群体药动学（Population Pharmacokinetics of Lamotrigine and Its N2-Glucuronide Metabolite in Chinese Patients With Epilepsy）
Yang, Hua; Zhang, Dongjie; Wei, Shifeng; More
Therapeutic Drug Monitoring. 46(5):649-657, October 2024.
14. 中国双相障碍患者稳态钠戊酸盐血浆浓度的回顾性分析：人口统计学和临床特征的影响（Retrospective Analysis of Steady-State Sodium Valproate Plasma Concentrations in Chinese Patients With Bipolar Disorder: Impact of Demographic and
Clinical Characteristics）
Qiming, Qian; Ping, Zheng; Huiqi, Li; More
Therapeutic Drug Monitoring. 46(5):658-663, October 2024.
15.难治性癫痫儿童鲁非酰胺和司替戊醇的药动学变异性：丹麦和挪威国家癫痫中心治疗药物监测的回顾性研究（Pharmacokinetic Variability of Rufinamide and Stiripentol in Children With Refractory Epilepsy: A Retrospective Study of Therapeutic
Drug Monitoring From the National Epilepsy Centers in Denmark and Norway）
Heger, Katrine; Burns, Margrete Larsen; Nikanorova, Marina; More
Therapeutic Drug Monitoring. 46(5):664-671, October 2024.
16.在偶尔和日常使用者中吸入Δ9-四氢大麻酚大麻市场产品的群体药动学分析中的剂量估算效用（Dose Estimation Utility in a Population Pharmacokinetic Analysis of Inhaled Δ9-Tetrahydrocannabinol Cannabis Market Products in Occasional and Daily
Users）
Henthorn, Thomas K.; Wang, George S.; Dooley, Greg; More
Therapeutic Drug Monitoring. 46(5):672-680, October 2024.

短篇通讯（Short Communication）
17.从万古霉素谷浓度监测转换为贝叶斯预测下的曲线下面积估算：资源有限环境下成本效益研究的短篇通讯（Switching Vancomycin Monitoring From Trough Concentration to Area Under the Curve Estimation by Bayesian Forecasting: A Short
Communication on a Cost-Benefit Study in Resource-Limited Settings）
Telles, João Paulo; Coelho, Diogenes Jr; Migotto, Karen Cristina; More
Therapeutic Drug Monitoring. 46(5):681-686, October 2024.
18. 产后妇女及其婴儿的布瑞哌唑、喹硫平、利培酮及其活性代谢物帕利哌酮的药动学（Pharmacokinetics of Brexpiprazole, Quetiapine, Risperidone, and Its Active Metabolite Paliperidone in a Postpartum Woman and Her Baby）
Konishi, Toru; Kitahiro, Yumi; Fujiwara, Naoko; More
Therapeutic Drug Monitoring. 46(5):687-691, October 2024.

编辑来信(Letter to the Editor)
19.危重患者连续与间歇性美罗培南给药的比较（Continuous Versus Intermittent Administration of Meropenem in Critically Ill Patients）
Launay, Manon; Perinel-Ragey, Sophie; Thiery, Guillaume
Therapeutic Drug Monitoring. 46(5):692-693, October 2024.

治疗药物监测 (Therapeutic Drug Monitoring)
December 2024 - Volume 46 - Issue 6
https://journals.lww.com/drug-monitoring/Pages/currenttoc.aspx

大查房（Grand Round）
1.肾功能不全患者使用模型指导的精准剂量优化达托霉素剂量（Daptomycin Dosage Optimization in Renal Impairment Using Model-Informed Precision Dosing）。
Sayadi, Hamza; Fromage, Yeleen; Labriffe, Marc; More
Therapeutic Drug Monitoring. 46(6):695-698, December 2024.

原创文章（Original Article）
2.儿童治疗药物监测中最佳替考拉宁谷浓度的系统综述和荟萃分析（ptimal Teicoplanin Trough Concentration With Therapeutic Drug Monitoring in Children: A Systematic Review and Meta-analysis）。
Hanai, Yuki; Oda, Kazutaka; Ueda, Takashi; More
Therapeutic Drug Monitoring. 46(6):699-709, December 2024.
3.肺移植患者中心导管和外周静脉穿刺血液样本中他克莫司水平的相关性（Ven-Cat研究）（Correlation Between Tacrolimus Levels in Blood Samples Obtained From Central Catheter and Peripheral Venipuncture in Lung Transplant Patients (Ven-Cat
Study)）。
Diego-Fernández, Verónica; García-Saiz, María del Mar; Llorente-Cantalapiedra, Ana; More
Therapeutic Drug Monitoring. 46(6):710-716, December 2024.
4. 3种不同方法用于血液中依维莫司定量的不可互换性：ACMIA、LTIA和UHPLC-MS/MS（Lack of Interchangeability Between 3 Different Methods for Quantification of Everolimus in Blood: ACMIA, LTIA, and UHPLC-MS/MS）。
Miyagi, Chika; Tanaka, Ryota; Shiraiwa, Ken; More
Therapeutic Drug Monitoring. 46(6):717-724, December 2024.
5.从床边到实验室：提高治疗药物监测准确性的血浆和全血中29种抗感染药物的前处理稳定性（From Bed to Bench: Pre-analytical Stability of 29 Anti-infective Agents in Plasma and Whole Blood to Improve Accuracy of Therapeutic Drug
Monitoring）。
Magreault, Sophie; Pierredon, Dorine; Akinotcho-Relouzat, Judith; More
Therapeutic Drug Monitoring. 46(6):725-734, December 2024.
6.回顾性研究评估新生儿万古霉素负荷剂量以达到治疗目标（A Retrospective Study Evaluating Neonatal Vancomycin Loading Doses to Achieve a Therapeutic Target）。
Fataar, Aaqilah; Pillay-Fuentes Lorente, Veshni; Decloedt, Eric H.; More
Therapeutic Drug Monitoring. 46(6):735-743, December 2024.
7.使用外部评估的群体药动学模型优化新生儿万古霉素初始剂量方案（Optimization of Vancomycin Initial Dosing Regimen in Neonates Using an Externally Evaluated Population Pharmacokinetic Model）。
Blouin, Mathieu; Métras, Marie-Élaine; El Hassani, Mehdi; More
Therapeutic Drug Monitoring. 46(6):744-755, December 2024.
8.开发和验证用于人体血浆微量样本中头孢洛唑和舒巴坦治疗药物监测的敏感液相色谱-串联质谱法（Development and Validation of a Sensitive Liquid Chromatography–Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of
Ceftolozane and Tazobactam in Human Plasma Microsamples）。
Conti, Matteo; Giorgi, Beatrice; Gatti, Milo; More
Therapeutic Drug Monitoring. 46(6):756-763, December 2024.
9.开发和验证高效液相色谱与紫外检测法用于人体血浆中比克替拉韦的定量（Development and Validation of a High-Performance Liquid Chromatography Coupled With Ultraviolet Detection Method for Quantification of Bictegravir in Human
Plasma）。
Xiao, Ran; Fu, Qiang; Chen, Ling; More
Therapeutic Drug Monitoring. 46(6):764-770, December 2024.
10.使用LC-MS/MS同时测定人体血浆中的瑞普替尼及其去甲基代谢物（Simultaneous Determination of Ripretinib and Its Desmethyl Metabolite in Human Plasma Using LC-MS/MS）。
Qian, Zhou-Yi; Wang, Ping; Wang, Zi-Yi; More
Therapeutic Drug Monitoring. 46(6):771-777, December 2024.
11.泰国儿科造血干细胞移植患者静脉注射白消安模型指导的精准剂量（ Model-Informed Precision Dosing of Intravenous Busulfan in Thai Pediatrics Undergoing Hematopoietic Stem Cell Transplantation）。
Puangpetch, Apichaya; Thomas, Fabienne; Anurathapan, Usanarat; More
Therapeutic Drug Monitoring. 46(6):778-785, December 2024.
12.基于模拟优化模型指导的每日一次和每日四次白消安在儿科患者中的采样时间表（Simulation-Based Optimization of Sampling Schedules for Model-Informed Precision Dosing of Once-Daily and 4-Times-Daily Busulfan in Pediatric Patients）。
Ben Hassine, Khalil; Daali, Youssef; Gloor, Yvonne; More
Therapeutic Drug Monitoring. 46(6):786-796, December 2024.
13.CYP1A2多态性及药物联合给药影响吡非尼酮的血药浓度和不良反应（CYP1A2 Polymorphism and Drug Co-administration Affect the Blood Levels and Adverse Effects of Pirfenidone）。
Yang, Xuerong; Wei, Jingxia; Yang, Yong; More
Therapeutic Drug Monitoring. 46(6):797-803, December 2024.
14.干血斑方法开发和临床验证用于LC-MS/MS分析Elexacaftor、Elexacaftor-M23、Tezacaftor、Tezacaftor-M1、Ivacaftor、Ivacaftor羧酸盐和羟甲基Ivacaftor（Dried Blood Spot Method Development and Clinical Validation for the Analysis of
Elexacaftor, Elexacaftor-M23, Tezacaftor, Tezacaftor-M1, Ivacaftor, Ivacaftor Carboxylate, and Hydroxymethyl Ivacaftor Using LC-MS/MS）。
Vonk, Steffie E. M.; van der Meer-Vos, Marloes; Kos, Renate; More
Therapeutic Drug Monitoring. 46(6):804-812, December 2024.
15.通过高效液相色谱与紫外检测和超高效液相色谱-串联质谱法定量血浆中Vadadustat浓度（Quantification of the Plasma Concentration of Vadadustat by High-Performance Liquid Chromatography with Ultraviolet Detection and Ultra-Performance
Liquid Chromatography-Tandem Mass Spectrometry）。
Yokoyama, Satoshi; Nakagawa, Junichi; Shimada, Michiko; More
Therapeutic Drug Monitoring. 46(6):813-819, December 2024.
16.维生素D补充、血清25(OH)D浓度和死亡风险之间的关系：一项使用NHANES 2007-2018数据的前瞻性队列研究（Association Among Vitamin D Supplementation, Serum 25(OH)D Concentrations, and Mortality Risk: A Prospective Cohort Study
Using NHANES 2007–2018 Data）。
Liu, Hong; Bai, Yu
Therapeutic Drug Monitoring. 46(6):820-827, December 2024.
17.奥氮平治疗药物监测：临床因素对精神病患者血浆浓度的影响（Therapeutic Drug Monitoring of Olanzapine: Effects of Clinical Factors on Plasma Concentrations in Psychiatric Patients）。
Ansermot, Nicolas; Vathanarasa, Harish; Ranjbar, Setareh; More
Therapeutic Drug Monitoring. 46(6):828-836, December 2024.

编辑来信(Letter to the Editor)
18.使氯氮平治疗药物监测成为最佳患者护理的必要条件（Making Clozapine Therapeutic Drug Monitoring Essential for Optimal Patient Care）。
Leung, Jonathan G.; Bye, Katie N.; Leloux, Megan R.; More
Therapeutic Drug Monitoring. 46(6):837-838, December 2024.
19.探索毒理遗传学在理解3-甲基甲卡西酮中毒中血液浓度与临床结果差异中的作用（Exploring the Role of Toxicogenetics in Understanding Discrepancies Between Blood Concentrations and Clinical Outcomes in 3- Methylmethcathinone
Intoxications）。
Drevin, Guillaume; Baudriller, Antoine; Briet, Marie; More
Therapeutic Drug Monitoring. 46(6):838-839, December 2024.
20.患有过度活跃膀胱综合征和全身炎症患者的索利那新和白细胞介素-6的血清谱及其与精神症状的关系（Serum Profiles of Solifenacin and Interleukin-6 and Their Relationship With Psychiatric Symptoms in a Patient With Overactive Bladder
Syndrome and Systemic Inflammation）。
Terasawa, Miho; Shibata, Kaito; Mimura, Akira; More
Therapeutic Drug Monitoring. 46(6):839-841, December 2024